| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
2 Department of Medicine, University of Perugia, Perugia, Italy
* To whom correspondence should be addressed. E-mail: wallacej{at}ucalgary.ca.
Products of cyclooxygenase (COX)-2 contribute to mucosal defence. Acetylation of COX-2 by aspirin has been shown to result in the generation of 15-(R)-epi-lipoxin A4, which exerts protective effects in the stomach. In gastritis, it is possible that lipoxin A4 makes a greater contribution to mucosal defence. We tested this hypothesis in the rat, using the iodoacetamide-induced gastritis model. Iodoacetamide was added to the drinking water for 5 days. Rats were then given aspirin and the extent of gastric damage was blindly assessed 3 h later. Gastric 15-epi-(R)-lipoxin A4 and prostaglandin E2 levels were determined. The effects of pretreatment with a selective COX-2 inhibitor, rofecoxib, and of a lipoxin receptor antagonist were assessed. Effects of aspirin and the other test drugs on leukocyte adherence within mesenteric venules were assessed by intravital microscopy. Aspirin elicited greater lipoxin synthesis in the inflamed than in the normal stomach, and there was reduced gastric damage. Rofecoxib inhibited lipoxin synthesis and exacerbated aspirin-induced damage. The lipoxin antagonist also exacerbated aspirin-induced damage. In rats with gastritis, aspirin reduced leukocyte adherence (in contrast to an increase in normal rats), and this effect was reversed by rofecoxib or by the lipoxin antagonist. These results support the notion that aspirin-triggered lipoxin synthesis via COX-2 makes an important contribution to mucosal defence in both the normal and inflamed stomach.
This article has been cited by other articles:
|
|
 |
|
  J. L. Wallace Prostaglandins, NSAIDs, and Gastric Mucosal Protection: Why Doesn't the Stomach Digest Itself? Physiol Rev, October 1, 2008; 88(4): 1547 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takeuchi, A. Tanaka, S. Kato, E. Aihara, and K. Amagase Effect of (S)-4-(1-(5-Chloro-2-(4-fluorophenyoxy)benzamido)ethyl) Benzoic Acid (CJ-42794), a Selective Antagonist of Prostaglandin E Receptor Subtype 4, on Ulcerogenic and Healing Responses in Rat Gastrointestinal Mucosa J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 903 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Nascimento-Silva, M. A. Arruda, C. Barja-Fidalgo, C. G. Villela, and I. M. Fierro Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells Am J Physiol Cell Physiol, September 1, 2005; 289(3): C557 - C563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. O. Zanardo, M. Perretti, and J. L. Wallace Annexin-1 is an endogenous gastroprotective factor against indomethacin-induced damage Am J Physiol Gastrointest Liver Physiol, March 1, 2005; 288(3): G481 - G486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. McMahon and C. Godson Lipoxins: endogenous regulators of inflammation Am J Physiol Renal Physiol, February 1, 2004; 286(2): F189 - F201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Wallace, S. R. Zamuner, W. McKnight, M. Dicay, A. Mencarelli, P. del Soldato, and S. Fiorucci Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation Am J Physiol Gastrointest Liver Physiol, January 1, 2004; 286(1): G76 - G81. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
